{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:09:41Z","timestamp":1793315381553,"version":"4.5.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.heliyon.2024.e30809","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T21:59:23Z","timestamp":1715032763000},"page":"e30809","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Comparative efficacy of immune checkpoint inhibitors combined with chemotherapy in patients with advanced driver-gene negative non-small cell lung cancer: A systematic review and network meta-analysis"],"prefix":"10.1016","volume":"10","author":[{"given":"Xuewen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiman","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huchen","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujia","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6248-6179","authenticated-orcid":false,"given":"Jun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.heliyon.2024.e30809_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN Estimates of incidence and Mortality Worldwide for 36 cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J. Clin."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e30809_bib2","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","article-title":"Non-small cell lung cancer: Epidemiology, screening, diagnosis, and treatment","volume":"94","author":"Duma","year":"2019","journal-title":"Mayo Clin. Proc."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30809_bib3","first-page":"7","article-title":"Cancer statistics","volume":"70","author":"Siegel","year":"2020","journal-title":"CA A Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e30809_bib4","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e30809_bib5","doi-asserted-by":"crossref","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","article-title":"Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Ettinger","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e30809_bib6","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jama.2019.11058","article-title":"Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review","volume":"322","author":"Arbour","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.heliyon.2024.e30809_bib7","article-title":"Therapeutic implications of tumor microenvironment in lung cancer: focus on immune checkpoint blockade","volume":"12","author":"Genova","year":"2021","journal-title":"Front. Immunol."},{"issue":"21","key":"10.1016\/j.heliyon.2024.e30809_bib8","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50","volume":"39","author":"Reck","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"10274","key":"10.1016\/j.heliyon.2024.e30809_bib9","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","article-title":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial","volume":"397","author":"Sezer","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e30809_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp. Mol. Med."},{"issue":"10183","key":"10.1016\/j.heliyon.2024.e30809_bib11","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e30809_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001064","article-title":"Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study","volume":"8","author":"Verschraegen","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"25","key":"10.1016\/j.heliyon.2024.e30809_bib13","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage IV or recurrent non-small-cell lung cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e30809_bib14","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2217\/imt.14.111","article-title":"Rationale for combining immunotherapy with chemotherapy","volume":"7","author":"Dalgleish","year":"2015","journal-title":"Immunotherapy"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e30809_bib15","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.21.01497","article-title":"First-line immunotherapy for non-small-cell lung cancer","volume":"40","author":"Reck","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e30809_bib16","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.annonc.2021.04.008","article-title":"Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189","volume":"32","author":"Rodr\u00edguez-Abreu","year":"2021","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e30809_bib17","first-page":"709","article-title":"[Immunotherapy for non-small cell lung cancer (NSCLC)]","volume":"63","author":"Frost","year":"2022","journal-title":"Inn. Med."},{"key":"10.1016\/j.heliyon.2024.e30809_bib18","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e30809_bib19","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J. Clin. Epidemiol."},{"issue":"27","key":"10.1016\/j.heliyon.2024.e30809_bib20","first-page":"2037","volume":"103","year":"2023","journal-title":"Zhonghua Yixue Zazhi"},{"issue":"Supplement 1","key":"10.1016\/j.heliyon.2024.e30809_bib21","article-title":"138P Randomized phase III study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced non-squamous non-small cell lung cancer (nsq-NSCLC): RATIONALE-304 updated analysis","volume":"16","author":"Lu","year":"2022","journal-title":"Immuno-Oncology and Technology"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e30809_bib22","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jtho.2021.11.018","article-title":"Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-Sq): a phase 3 trial","volume":"17","author":"Ren","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.heliyon.2024.e30809_bib23","unstructured":"Higgins JP, Green S. Wiley-Blackwell; 2008."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e30809_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLoS One"},{"issue":"7414","key":"10.1016\/j.heliyon.2024.e30809_bib25","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.heliyon.2024.e30809_bib26","article-title":"Network meta-analysis: application and practice using R software","volume":"41","author":"Shim","year":"2019","journal-title":"Epidemiol Health"},{"key":"10.1016\/j.heliyon.2024.e30809_bib27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12874-016-0184-5","article-title":"Two new methods to fit models for network meta-analysis with random inconsistency effects","volume":"16","author":"Law","year":"2016","journal-title":"BMC Med. Res. Methodol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e30809_bib28","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/10618600.1998.10474787","article-title":"General methods for monitoring convergence of iterative simulations","volume":"7","author":"Brooks","year":"1998","journal-title":"J. Comput. Graph Stat."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e30809_bib29","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jtho.2022.12.017","article-title":"Camrelizumab plus carboplatin and pemetrexed as first-line treatment for advanced nonsquamous NSCLC: extended follow-up of CameL phase 3 trial","volume":"18","author":"Zhou","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e30809_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100273","article-title":"First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update","volume":"6","author":"Reck","year":"2021","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e30809_bib31","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1200\/JCO.22.00727","article-title":"Toripalimab plus chemotherapy for patients with treatment-naive advanced non-small-cell lung cancer: a multicenter randomized phase III trial (CHOICE-01)","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e30809_bib32","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S1470-2045(21)00650-1","article-title":"Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial","volume":"23","author":"Zhou","year":"2022","journal-title":"Lancet Oncol."},{"issue":"30","key":"10.1016\/j.heliyon.2024.e30809_bib33","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1200\/JCO.2016.71.7629","article-title":"Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer","volume":"35","author":"Govindan","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e30809_bib34","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jtho.2020.11.025","article-title":"Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 trial","volume":"16","author":"Nishio","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e30809_bib35","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1111\/cas.14980","article-title":"Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan Study","volume":"112","author":"Horinouchi","year":"2021","journal-title":"Cancer Sci."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e30809_bib36","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study","volume":"41","author":"Novello","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e30809_bib37","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.lungcan.2022.07.013","article-title":"Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study","volume":"171","author":"Zhang","year":"2022","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e30809_bib38","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.jtho.2021.04.011","article-title":"Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: results from a randomized, double-blind, phase 3 trial (ORIENT-12)","volume":"16","author":"Zhou","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e30809_bib39","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1200\/JCO.22.00975","article-title":"Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study","volume":"41","author":"Johnson","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e30809_bib40","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jamaoncol.2021.0366","article-title":"Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: a phase 3 randomized clinical trial","volume":"7","author":"Wang","year":"2021","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30809_bib41","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jtho.2020.09.015","article-title":"Long-term overall survival from KEYNOTE-021 cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous NSCLC","volume":"16","author":"Awad","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"17","key":"10.1016\/j.heliyon.2024.e30809_bib42","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2011.38.4032","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB\/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study","volume":"30","author":"Lynch","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e30809_bib43","doi-asserted-by":"crossref","DOI":"10.1053\/j.seminoncol.2022.06.009","article-title":"Non-small cell lung cancer in the era of immunotherapy","author":"Huang","year":"2022","journal-title":"Semin. Oncol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e30809_bib44","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1470-2045(23)00108-0","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study","volume":"24","author":"Xu","year":"2023","journal-title":"Lancet Oncol."},{"issue":"15","key":"10.1016\/j.heliyon.2024.e30809_bib45","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1158\/1078-0432.CCR-22-0666","article-title":"Neoadjuvant chemoimmunotherapy for the treatment of locally advanced head and neck squamous cell carcinoma: a single-arm phase 2 clinical trial","volume":"28","author":"Zhang","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e30809_bib46","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1002\/1878-0261.12851","article-title":"Targeting immunogenic cell death in cancer","volume":"14","author":"Ahmed","year":"2020","journal-title":"Mol. Oncol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e30809_bib47","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.immuni.2015.11.024","article-title":"Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy","volume":"44","author":"Pfirschke","year":"2016","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e30809_bib48","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1007\/s10637-022-01232-8","article-title":"The efficacy and safety of immune checkpoint inhibitor plus chemotherapy in patients with advanced non-small-cell lung cancer: a meta-analysis","volume":"40","author":"Meng","year":"2022","journal-title":"Invest. N. Drugs"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30809_bib49","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2169531","article-title":"Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: a systematic evaluation and meta-analysis","volume":"19","author":"Lu","year":"2023","journal-title":"Hum. Vaccines Immunother."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e30809_bib50","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1158\/2326-6066.CIR-16-0325","article-title":"Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC","volume":"5","author":"Tumeh","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e30809_bib51","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1007\/s00262-018-2239-4","article-title":"Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)","volume":"67","author":"Schmid","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30809_bib52","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1186\/s12885-019-6073-7","article-title":"Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy","volume":"19","author":"Bilen","year":"2019","journal-title":"BMC Cancer"},{"issue":"52","key":"10.1016\/j.heliyon.2024.e30809_bib53","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aba0759","article-title":"Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis","volume":"5","author":"Lee","year":"2020","journal-title":"Sci Immunol"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e30809_bib54","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11910-018-0877-8","article-title":"Management of brain metastases in the new era of checkpoint inhibition","volume":"18","author":"Lauko","year":"2018","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"14","key":"10.1016\/j.heliyon.2024.e30809_bib55","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","article-title":"Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System","volume":"22","author":"Barnholtz-Sloan","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e30809_bib56","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1200\/JOP.19.00357","article-title":"Management of brain metastases in non-small-cell lung cancer","volume":"15","author":"Ernani","year":"2019","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.heliyon.2024.e30809_bib57","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.canlet.2020.12.043","article-title":"Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: mechanisms, advances, and challenges","volume":"502","author":"Zhou","year":"2021","journal-title":"Cancer Lett."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e30809_bib58","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12123707","article-title":"Outcome of patients with NSCLC and brain metastases treated with immune checkpoint inhibitors in a 'real-life' setting","volume":"12","author":"Skribek","year":"2020","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e30809_bib59","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial","volume":"16","author":"Rizvi","year":"2015","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e30809_bib60","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.heliyon.2024.e30809_bib61","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"10066","key":"10.1016\/j.heliyon.2024.e30809_bib62","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30809_bib63","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41419-021-03410-7","article-title":"Genomic profiles and tumor immune microenvironment of primary lung carcinoma and brain oligo-metastasis","volume":"12","author":"Song","year":"2021","journal-title":"Cell Death Dis."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e30809_bib64","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/annonc\/mdz207","article-title":"Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer","volume":"30","author":"Kudo","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.heliyon.2024.e30809_bib65","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.pharmthera.2018.01.003","article-title":"Combining chemotherapy with PD-1 blockade in NSCLC","volume":"186","author":"Mathew","year":"2018","journal-title":"Pharmacol. Ther."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e30809_bib66","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.jtho.2021.06.020","article-title":"Outcomes with pembrolizumab plus platinum-based chemotherapy for patients with NSCLC and stable brain metastases: pooled analysis of KEYNOTE-021, -189, and -407","volume":"16","author":"Powell","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"13","key":"10.1016\/j.heliyon.2024.e30809_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23137068","article-title":"Immunotherapy in NSCLC patients with brain metastases","volume":"23","author":"Buriolla","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e30809_bib68","doi-asserted-by":"crossref","first-page":"8560","DOI":"10.1021\/acsnano.7b04092","article-title":"Drug delivery strategies for platinum-based chemotherapy","volume":"11","author":"Browning","year":"2017","journal-title":"ACS Nano"},{"key":"10.1016\/j.heliyon.2024.e30809_bib69","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: molecular mechanisms of action","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e30809_bib70","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JOP.18.00474","article-title":"Treatment of advanced non-small-cell lung cancer: from chemotherapy to chemoimmunotherapy","volume":"14","author":"Pirker","year":"2018","journal-title":"J Oncol Pract"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30809_bib71","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/CCO.0000000000000592","article-title":"Chemotherapy remains a cornerstone in the treatment of nonsmall cell lung cancer","volume":"32","author":"Pirker","year":"2020","journal-title":"Curr. Opin. Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30809_bib72","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41568-020-00308-y","article-title":"The rediscovery of platinum-based cancer therapy","volume":"21","author":"Rottenberg","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e30809_bib73","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1158\/2159-8290.CD-20-1680","article-title":"The next decade of immune checkpoint therapy","volume":"11","author":"Sharma","year":"2021","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e30809_bib74","doi-asserted-by":"crossref","first-page":"340","DOI":"10.6004\/jnccn.2023.0020","article-title":"NCCN Guidelines\u00ae insights: non-small cell lung cancer, version 2.2023","volume":"21","author":"Ettinger","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e30809_bib75","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","article-title":"Predictive biomarkers for checkpoint inhibitor-based immunotherapy","volume":"17","author":"Gibney","year":"2016","journal-title":"Lancet Oncol."},{"issue":"21","key":"10.1016\/j.heliyon.2024.e30809_bib76","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad","year":"2021","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e30809_bib77","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 expression as a predictive biomarker in cancer immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol. Cancer Therapeut."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e30809_bib78","doi-asserted-by":"crossref","first-page":"706","DOI":"10.5858\/arpa.2018-0584-CP","article-title":"The cancer immunotherapy biomarker testing landscape","volume":"144","author":"Walk","year":"2020","journal-title":"Arch. Pathol. Lab Med."},{"key":"10.1016\/j.heliyon.2024.e30809_bib79","doi-asserted-by":"crossref","first-page":"k3529","DOI":"10.1136\/bmj.k3529","article-title":"Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis","volume":"362","author":"Shen","year":"2018","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e30809_bib80","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e30809_bib81","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1158\/1078-0432.CCR-17-1341","article-title":"Early assessment of lung cancer immunotherapy response via circulating tumor DNA","volume":"24","author":"Goldberg","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e30809_bib82","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/jamaoncol.2020.2295","article-title":"Association of circulating tumor DNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with triple-negative breast cancer: preplanned secondary analysis of the BRE12-158 randomized clinical trial","volume":"6","author":"Radovich","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.heliyon.2024.e30809_bib83","article-title":"Circulating tumor DNA predicts the response and prognosis in patients with early breast cancer receiving neoadjuvant chemotherapy","volume":"4","author":"Li","year":"2020","journal-title":"JCO Precis Oncol"},{"issue":"24","key":"10.1016\/j.heliyon.2024.e30809_bib84","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e30809_bib85","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1001\/jamaoncol.2022.2719","article-title":"Evaluation of clinical outcomes of icotinib in patients with clinically diagnosed advanced lung cancer with EGFR-sensitizing variants assessed by circulating tumor DNA testing: a phase 2 nonrandomized clinical trial","volume":"8","author":"Xu","year":"2022","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e30809_bib86","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/JCO.22.00364","article-title":"Circulating tumor DNA identifies diverse landscape of acquired resistance to anti-epidermal growth factor receptor therapy in metastatic colorectal cancer","volume":"41","author":"Topham","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e30809_bib87","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-23-0604","article-title":"HLA-I evolutionary divergence confers response to PD-1 blockade plus chemotherapy in untreated advanced non-small-cell lung cancer","author":"Jiang","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e30809_bib88","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1038\/s41591-022-01977-y","article-title":"Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial","volume":"28","author":"Gogishvili","year":"2022","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e30809_bib89","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e30809_bib90","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.jtho.2020.03.028","article-title":"Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial","volume":"15","author":"Jotte","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"21","key":"10.1016\/j.heliyon.2024.e30809_bib91","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e30809_bib92","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e30809_bib93","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e30809_bib94","doi-asserted-by":"crossref","first-page":"977","DOI":"10.2169\/internalmedicine.3928-19","article-title":"Renal effects after pembrolizumab treatment for non-small cell lung carcinoma","volume":"59","author":"Oki","year":"2020","journal-title":"Intern. Med."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e30809_bib95","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1111\/1759-7714.13177","article-title":"Myasthenia gravis and myopathy after nivolumab treatment for non-small cell lung carcinoma: a case report","volume":"10","author":"Kim","year":"2019","journal-title":"Thorac Cancer"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024068403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024068403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:20:03Z","timestamp":1790238003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024068403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":95,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2405844024068403"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e30809","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy of immune checkpoint inhibitors combined with chemotherapy in patients with advanced driver-gene negative non-small cell lung cancer: A systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e30809","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e30809"}}